## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

Claim 1 (currently amended): A vector for the surface expression of antibiotic antibiotics, which comprises:

one or more than two genes selected from the group consisting of pgsB, pgsC and pgsA, said genes encoding a poly-gamma-glutamate synthetase complex; and a gene encoding P5 peptide with having antibacterial, antifungal and anticancer activities <u>fused</u> with said gene encoding a poly-gamma-glutamate synthetase complex, wherein P5 peptide is encoded by the base sequence of SEQ ID NO: 4.

Claim 2 (original): The vector according to claim 1, wherein said pgsB, pgsC and pgsA genes have the base sequences described in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.

Claim 3 (original): The vector according to claim 1, wherein the vector contains the pgsA gene among the genes encoding the poly-gamma-glutamate synthetase complex.

Claim 4 (cancelled)

Claim 5 (currently amended): The vector according to claim 1, said vector is pHCE1LB:pgsA-P5 for the surface expression of antibiotic antibiotics, which expresses said antibiotic on the surface of gram-negative and gram positive bacteria.

Claim 6 (previously presented): A microorganism transformed with the vector of claim 1.

Claim 7 (original): E. Coli (KCTC 10350BP) transformed with the vector pHCE1LB:pgsA-P5 of claim 5.

Claim 8 (previously presented): A lactic acid-forming bacteria transformed with the vector of claim 1.

Claim 9 (cancelled)

Claim 10 (cancelled)

Claim 11 (previously presented): A pharmaceutical composition and suspension of the same for antibacterial, antifungal or anticancer application, which comprises, as an active ingredient, the lactic acid-forming bacteria according to claim 8 and having the peptide antibiotic P5 expressed on their surface.

Claim 12 (original): The pharmaceutical composition according to claim 11, wherein said active ingredient is heat-treated.

Claims 13-22 (cancelled)